Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

“Think about the timing for when an importer would agree to make the purchase and by the time it would arrive at a retailers’ outlet,” she says. Late this spring, farmers found themselves in a tight ...

For a new series, Times journalists are speaking with scientists whose research has ended as a result of policy changes by the Trump administration. By Alan Burdick Under Trump, the N.I.H. is ...